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Onchocerciasis control in South Sudan
Mounir Christo lado luggaa and fasil Chaneb
This paper gives an overview of  the Community Directed Treatment 
with Ivermectin (CTDI) projects in 2009. Data from the 2010 
report will be published when it is available. Box 1 at the end of  this 
article gives treatment guidelines.
Background
Onchocerciasis is an insect-borne disease caused by the 
parasite Onchocerca volvulus and transmitted by blackflies 
of  the species Simulium damnosum. It is often called ‘river 
blindness’ because the blackfly lives in fertile riverside 
areas, that frequently remain uninhabited for fear of  
infection. Onchocerca volvulus is almost exclusively a parasite 
of  humans. Adult worms live in nodules in the body 
where the female worms produce large numbers of  first-
stage larvae known as microfilariae. These migrate from 
the nodules to the sub-epidermal layer of  the skin where 
they are ingested by blackflies. The microfilariae develop 
in the body of  the blackfly and are transmitted to humans 
when the fly bites them (1). 
Microfilariae cause eye lesions in humans. They are 
found in all the internal tissues of  the eye, except the 
lens, where they cause inflammation, bleeding, and other 
complications that ultimately lead to blindness (1). The 
patient initially complains of  itching, but blindness results 
from chorioretinitis and optic neuritis.
Between 1995 and 2002, Rapid Epidemiological 
Assessment (REA) was conducted in South Sudan 
by various Non-Government Organizations (NGOs) 
supporting Onchocerciasis Control in areas where 
they provided health services. However, in 2003, the 
African Program for Onchocerciasis Control (APOC) in 
collaboration with the Southern Sudan Onchocerciasis 
Task Force carried out Rapid Epidemiological Mapping 
of  Onchocerciasis (REMO) in the country, partly to 
validate available historical epidemiological data (2). 
Results confirmed that onchocerciasis was a disease of  
public health importance in the country (3).
Current activities
Activities to control onchocerciasis were started in the 
mid-1990s and Community Directed Treatment with 
Ivermectin (CTDI) projects were developed at the 
inception of  the autonomous Government of  Southern 
Sudan in 2005. There are currently five CTDI projects. 
Onchocerciasis is endemic in all the states except Unity 
State. The main endemic foci are located in Western 
Equatoria, Northern Bahr el Ghazal and Western Bahr el 
Ghazal (3) . In some villages more than 80% of  individuals 
have palpable nodules and more than 12% are blind (4). 
training 
In 2009, a total of  9,268 Community Directed Distributors 
(CDDs), 1,094 Health Workers and 1,253 Community 
Leaders were trained on onchocerciasis activities (5).
planned coverage
Over the five CDTI project areas:
Total population targeted = 5,605,726• 
Ultimate Treatment Goal (UTG) = 4,708,810 • 
people
Annual Treatment Objective (ATO) = 3,019,766 • 
people.
Figure 1 shows the planned coverage by CDTI project. 
Actual coverage
A total of  5,701 villages have been treated out of  6,503 
endemic villages giving a geographical coverage of  87.7% 
see Figure 2. The total population that has been treated 
is 3,012,058 giving a therapeutic coverage of  53.7% - see 
Figure 3 (5).  
discussion
Much progress has been made in fighting onchocerciasis 
in the five project areas through annual distribution of  
ivermectin. This relieves the severe skin itching caused 
by the disease. Ivermectin kills the larvae but not the 
adult worms of  Onchocerca volvulus so annual or biannual 
treatments are required to prevent resurgence. However, 
studies in Mali and Senegal showed that after 15 to 17 
years of  six-monthly or annual treatments, only a few 
infections remained in the human population (6).
The Ministry of  Health, South Sudan has now 
embarked on an Integrated Neglected Tropical Disease 
Control strategy for sustainable and effective interventions 
to combat the human suffering caused by Neglected 
Tropical Diseases (NTDs) (7). One method, applicable to 
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Figure 1. Total population, Ultimate Treatment Goals (UTG) and 
Annual Treatment Objectives (ATO) in the CTDI projects.
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the control or elimination of  seven NTDs – lymphatic 
filariasis, onchocerciasis, schistosomiasis, soil-transmitted 
helminths (i.e. ascariasis, trichuriasis and hookworm 
disease) and trachoma – is Mass Drug Administration 
(MDA) of  Preventive Chemotherapy (PCT) through an 
integrated approach (8).
mDA packages
The MDA Packages will contain any of  five drugs - 
ivermectin, praziquantel, albendazole (or mebendazole), 
azithromycin, tetracycline - depending on the co-
endemicity of  diseases and whether the intervention 
threshold is exceeded. For areas where helminth diseases 
- onchocerciasis, lymphatic filariasis, schistosomiasis 
and soil-transmitted helminths – are co-endemic, 
administration of  a MDA package will be relatively 
straightforward, because all of  the required drugs have 
been cleared for co-administration. However praziquantel 
should only be administered alongside other anthelminths 
after at least one separate round of  MDA, to avoid 
adverse events in individuals with high worm loads. 
Where trachoma is endemic, a minimum of  one week 
has to elapse between administration of  antihelminth and 
azithromycin, because there is insufficient information 
to guarantee the safe co-administration of  these drugs. 
Areas endemic for lymphatic filariasis and highly endemic 
for L. loa, but not onchocerciasis, will be excluded from 
MDA packages as the risk of  adverse events is thought to 
outweigh the advantages of  treatment (7).
In implementation units where the intervention 
threshold for a particular disease or combination of  
diseases has been exceeded, presumptive treatment will be 
delivered. This means that no diagnostic tool will be used 
and that a large number of  infected and uninfected people 
will be treated. In areas where only helminth diseases are 
being treated this is feasible because anthelminths have 
an excellent safety record, adverse reactions are minimal 
and transient, and severe adverse effects are extremely 
infrequent (7, 8). 
Though this presents great challenges, it also 
offers great potential to increase treatment coverage 
for co-endemic NTDs, integrate more complex case-
management into facility-based health care delivery and 
strengthen the link between 
communities and health 
facilities. This unprecedented 
opportunity to build 
evidence-based systems for 
NTD control or elimination 
needs to be maximised now 
while rebuilding of  the health 
sector is ongoing (9).
References:
World Health 1. 
Organization. Priority Eye 
Diseases, Onchocerciasis. 2001. http://www.who.int/
blindness/causes/priority/en/index3.html
African Program for Onchocerciasis Control (APOC). 2. 
2005. Rapid assessment of  loiasis and onchocerciasis in 
Southern Sudan. Mission Report.
Ministry of  Health, Government of  Southern Sudan. 3. 
2008. Neglected tropical diseases and their control 
in Southern Sudan. Situation analysis, intervention 
options, appraisal and gap analysis. 
Mukhtar MM et al. The Burden of  Onchocererca 4. 
volvulus in Sudan.  Ann. Trop. Med. Parasitol. 1998 92 
(Suppl. 1): 129-131.
Southern Sudan Task Force Annual Report. 2009.5. 
World Health Organization. Elimination of  river 6. 
blindness feasible: WHO study shows that areas in Mali 
and Senegal require no further mass treatment. WHO 
TDR. 2009 21 July at http://dx.plos.org/10.1371/journal.
pntd.0000497
Integrated Control of  Neglected Tropical Diseases. 7. 
National Strategic Plan, Southern Sudan. 2008-2011
World Health Organization. Preventive Chemotherapy 8. 
in Human Helminthiasis: coordinated use of  
anthelminthic drugs in control interventions: a manual 
for health professionals and programme managers. 
WHO, Geneva. 2006.
Rumunu J. et al. Southern Sudan: An opportunity for 9. 
NTD control and elimination? PubMed. Trends Parasitol; 
2009. 25(7): 301–307.
Figure 2. Geographical coverage in the CDTI 







15-25 90-119 1 tablet (3mg) Oral once
26-44 120-139 2 tablets (6mg) Oral once
45-64 140-159 3 tablets (9mg) Oral once
65 and above    160 and 
above
4 tablets (12mg) Oral once
box 1. Recommended treatment guidelines using Ivermectin  
